CEL-383 is under clinical development by Celsius Therapeutics and currently in Phase I for Inflammatory Bowel Disease. According to GlobalData, Phase I drugs for Inflammatory Bowel Disease have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CEL-383’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CEL-383 overview
CEL-383 is under development for the treatment of inflammatory bowel disease. The drug candidate is an anti-TREM1 antibody which is being developed based on Celsius artificial intelligence (AI) enabled Single Cell Observations for Precision Effect (SCOPE) platform. It is administered through intravenous route.
Celsius Therapeutics overview
Celsius Therapeutics is a biotechnology company that carries out single-cell genomic analysis to discover and develop precision medicines for autoimmune diseases and cancer. It is investigating CEL383, an anti-TREM1 mAb program targeting inflammatory bowel disease (IBD) and other related targets. The company is also evaluating Ledenika and Lassen mAb programs against solid tumors and drugs to treat colorectal and other oncology targets. Celsius Therapeutics utilizes its proprietary SCOPE platform technology that analyzes cells and generates gene expression data points from tissue samples of patients with IBD and solid tumors. The company was funded by Third Rock Ventures, Catalio Capital Management, Casdin Capital and others. Celsius Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of CEL-383’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
